Kyverna Therapeutics (KYTX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Kyverna Therapeutics (KYTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Kyverna Therapeutics (KYTX) has a market capitalization of approximately
Kyverna Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Kyverna Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Kyverna Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Kyverna Therapeutics carries a debt-to-equity ratio of 0.17x and a current ratio of 8.15x, with a market beta of 1.88. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kyverna Therapeutics (KYTX) the key facts are: market cap
Get Kyverna Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.